Alzheimer’s disease (AD) is a global health challenge influenced by genetic, lifestyle, and environmental factors. Though its precise onset remains unclear, AD is characterized by amyloid-β plaques, tau tangles, and neuronal loss, leading to cognitive impairments. The adoption of a clinical-biological biomarker framework enables earlier intervention and personalized treatment, driving research toward refining biomarkers for improved diagnosis and prognosis. Magnetic resonance imaging (MRI) biomarkers, including medial temporal lobe atrophy (MTA), hippocampal volume reduction, and ventricular enlargement, are valuable for detecting brain changes. Traditionally, manual segmentation has been the gold standard, but automated volumetric tools using machine learning are now enhancing accuracy and efficiency. This study evaluates icobrain dm, an automated brain volumetry tool for clinical MRI scans, assessing its feasibility for routine clinical integration. By addressing validation, standardization, and biomarker integration challenges, this research aims to enhance AD detection, staging, and management, supporting personalized treatment strategies. Our findings show that icobrain dm demonstrates robust intra- and inter-scanner reliability (mean DSC > 0.88) and high reproducibility (mean CV < 3%) across global, cortical, and subcortical structures. Icobrain’s automated MTA assessment, expressed as the ratio between inferior lateral ventricle and hippocampal volumes, correlates strongly with visual MTA ratings across cognitive decline stages. However, automated hippocampal volumes alone exhibit moderate correlation, highlighting the inferior lateral ventricle's crucial role in MTA assessment. Comparing automated MTA scores with age-matched healthy controls could aid in clinical interpretation of medial temporal atrophy severity. Additional findings suggest icobrain dm enhances diagnostic certainty by assessing hippocampal and temporal cortex volumes in AD. Brain age and Brain-Predicted Age Difference (BPAD) correlate with accelerated brain aging beyond chronological age and classify cognitive states effectively. Notably, heavy alcohol consumption accelerates brain aging, as reflected in significant BPAD differences between heavy drinkers and non-drinkers. The development of event-based models (EBMs) for AD staging has shown promising generalizability and reliability across datasets. Notably, amnestic Mild Cognitive Impairment (MCI) subjects exhibit higher biomarker event scores than non-amnestic MCI, improving precision in clinical trial recruitment. Additionally, analysis of white matter hyperintensity (WMH), neuropsychological scores, and hippocampal volumes underscores the complex relationship between WMH and cognitive function. Despite progress, challenges remain in validating automated measurements across diverse populations. Tailored EBMs for AD subtypes are crucial for accurate staging, and further research is needed to interpret the interplay between WMH load and cognitive outcomes. Addressing these challenges will enhance the adoption of automated MRI analysis, improving AD diagnosis and patient care.